EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives

Nikita Chernyi iD, Darina Gavrilova, Mane Saruhanyan, Ezekiel S Oloruntimehin iD, Alexander Karabelsky iD, Evgeny Bezsonov iD, Alexander Malogolovkin iD

Biomolecules · 2024

DOI: 10.3390/biom14070854 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Nikita Chernyi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Virology, First Moscow State Medical University (Sechenov University), Moscow 119435, Russia. Hauptthemen laut MEDLINE: Genetic Therapy, Hemophilia A, Factor VIII. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academic Leadership Program Priority 2030 by the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical…, The grant of the state program of the «Sirius» Federal Territory «Scientific and technological development of the «Sirius» Federal Territory», Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical University of the Ministry of Health of the Russ….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the well-known X-linked genetic disorders is hemophilia, which could be hemophilia A as a result of a mutation in the F8 (factor VIII) gene or hemophilia B as a result of a mutation in the F9 (factor IX) gene, leading to insufficient levels of the proteins essential for blood coagulation cascade. In patients with severe hemophilia, factor VIII or factor IX activities in the blood plasma are considerably low, estimated to be less than 1%. This is responsible for spontaneous or post-traumatic bleeding episodes, or both, leading to disease complications and death. Current treatment of hemophilia relies on the prevention of bleeding, which consists of expensive lifelong replacement infusion therapy of blood plasma clotting factors, their recombinant versions, or therapy with recombinant monoclonal antibodies. Recently emerged gene therapy approaches may be a potential game changer that could reshape the therapeutic outcomes of hemophilia A or B using a one-off vector in vivo delivery and aim to achieve long-term endogenous expression of factor VIII or IX. This review examines both traditional approaches to the treatment of hemophilia and modern methods, primarily focusing on gene therapy, to update knowledge in this area. Recent technological advances and gene therapeutics in the pipeline are critically reviewed and summarized. We consider gene therapy to be the most promising method as it may overcome the problems associated with more traditional treatments, such as the need for constant and expensive infusions and the presence of an immune response to the antibody drugs used to treat hemophilia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyHemophilia AFactor VIIIHumansFactor IXHemophilia BAnimalsGenetic Vectors

Stichwörter der Autor:innen

AAVCRISPR-Cas-9bispecific antibodiesgene therapyhemophiliaimmune tolerance inductionviral vectors

Substanzen

Factor VIIIFactor IX

Autor:innen und Institutionen

  • Laboratory of Molecular Virology, First Moscow State Medical University (Sechenov University), Moscow 119435, Russia.
  • Department of Biology and General Genetics, First Moscow State Medical University (Sechenov University), Moscow 105043, Russia.
  • Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354530, Russia.

ORCID-Profile: Nikita Chernyi, Ezekiel S Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, Alexander Malogolovkin

Förderung

  • Academic Leadership Program Priority 2030 by the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical…
  • The grant of the state program of the «Sirius» Federal Territory «Scientific and technological development of the «Sirius» Federal Territory»
  • Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical University of the Ministry of Health of the Russ…
  • «Sirius» Federal Territory Scientific and technological development of the «Sirius» Federal Territory

Zitieren

APA

Chernyi, N., Gavrilova, D., Saruhanyan, M., Oloruntimehin, E. S., Karabelsky, A., Bezsonov, E., & Malogolovkin, A. (2024). Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives. Biomolecules. https://doi.org/10.3390/biom14070854

Vancouver

Chernyi N, Gavrilova D, Saruhanyan M, Oloruntimehin ES, Karabelsky A, Bezsonov E, et al. Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives. Biomolecules. 2024. doi:10.3390/biom14070854

BibTeX
@article{Chernyi2024,
  author = {Chernyi, Nikita and Gavrilova, Darina and Saruhanyan, Mane and Oloruntimehin, Ezekiel S and Karabelsky, Alexander and Bezsonov, Evgeny and Malogolovkin, Alexander},
  title = {Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14070854}
}
Kostenlos starten →